February 22, 2013

Securities & Exchange Commission
450 Fifth Street, NW
Washington, DC 20549

Attn.: Document Control



RE:	American Depositary Shares
evidenced by One (1) American
Depositary Receipts representing fifty
(50) Ordinary Shares of
China Pharmaceutical Group Limited
(Form F6 File No. 33395632)


Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the
Securities Act of 1933, as amended, on
behalf of BNY Mellon, as Depositary for
securities against which American Depositary
Receipts are to be issued, we attach a copy of
the new prospectus (Prospectus) reflecting the
change in name for China Pharmaceutical
Group Limited.

As required by Rule 424(e), the upper right
hand corner of the Prospectus cover page has
a reference to Rule 424(b)(3) and to the file
number of the registration statement to which
the Prospectus relates.

Pursuant to Section III B of the General
Instructions to the Form F6 Registration
Statement, the Prospectus consists of the
ADR certificate with revised name change for
China Pharmaceutical Group Limited.

The Prospectus has been revised to reflect
the new name, and has been overstamped
with:

Effective February 22, 2013 the
Companys name changed to CSPC
Pharmaceutical Group Limited

Please contact me with any questions or
comments at 212 8158162



Arlene C. Villareal
The Bank of New York Mellon  ADR
Division


Encl.
CC: Paul Dudek, Esq. (Office of International
Corporate Finance)








101 Barclay Street, 22nd Floor West, New York, NY 10286